MedTrace Logo

Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose

NCT04815590 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2022-11-17

No results posted yet for this study

Summary

This pilot study will evaluate the feasibility and clinical utility of extended-release injectable buprenorphine (XR-BUP) for the treatment of opioid use disorder (OUD) among individuals at high-risk for overdose (OD).

Conditions

Sponsors & Collaborators

  • Indivior Inc.

    collaborator INDUSTRY

  • BC Centre on Substance Use

    lead OTHER

Principal Investigators

  • M. Eugenia Socias, MD, MSc. · Assistant Professor, Department of Medicine, University of British Columbia

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-17
Primary Completion
2023-10-17
Completion
2023-10-17

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04815590 on ClinicalTrials.gov